Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Down 39.3% in June

Posted by Stanley Muller on Jul 1st, 2026

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 191,896 shares, a decline of 39.3% from the May 31st total of 315,885 shares. Based on an average daily trading volume, of 6,417,679 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On Genenta Science

Several large investors have recently bought and sold shares of GNTA. Eurizon Capital SGR S.p.A. bought a new stake in shares of Genenta Science during the 4th quarter valued at $536,000. Ghisallo Capital Management LLC bought a new position in shares of Genenta Science in the 4th quarter worth $482,000. Weiss Asset Management LP acquired a new stake in shares of Genenta Science during the fourth quarter worth $480,000. Norges Bank acquired a new stake in shares of Genenta Science during the fourth quarter worth $337,000. Finally, Alyeska Investment Group L.P. bought a new stake in Genenta Science in the fourth quarter valued at about $328,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Genenta Science Trading Down 2.7%

Genenta Science stock traded down $0.05 during trading hours on Wednesday, reaching $1.79. 108,074 shares of the company’s stock traded hands, compared to its average volume of 1,263,830. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16. Genenta Science has a fifty-two week low of $0.55 and a fifty-two week high of $10.00. The firm’s 50 day moving average is $1.19 and its 200-day moving average is $1.10.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Get Our Latest Analysis on Genenta Science

Genenta Science Company Profile

(Get Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.